 Tel:+86-755-26890807

UPCOMING EVENTS: São Paulo, Hospitalar 2024:E-390-5

News Detail
Home / News / Health Watch / Diagnostics for SLE: The Autoimmune Disease Made The Headline

Diagnostics for SLE: The Autoimmune Disease Made The Headline

Author: Site Editor     Publish Time: 2023-12-15      Origin: Site

Inquire

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Health Watch

2023-12-15


Hongkong born actress Kathy Chow, suddenly died at her 57 in Beijing on December 11. She was known by many for her role in TV series The Heaven Sword And Dragon Sabre (1994), an adaptation of late writer Louis Cha’s martial arts novel.
Reports had previously surfaced suggesting that she was battling the autoimmune disease lupus, which had reportedly impacted her professional endeavors.
Soon after the announcement, a photo of Chow’s medical records began circulating online.According to the leaked document, the patient, who lived alone, suffered from high blood pressure and systemic lupus erythematosus(SLE).

Her shocking death news soon arise discussions online on the the disease SLE.




What is SLE?


Systemic Lupus Erythematosus (SLE) is a heterogeneous incurable autoimmune disorder characterized by both B- and T-cell dysfunction that results in immune-mediated multi-system tissue damage.



What is the diagnostics criteria for SLE

The standard testing criteria for SLE is positice ANA. In 2019, the 2019 EULAR/ACR classification criteria for SLE include positive ANA at least once as obligatory entry criterion; followed by additive weighted criteria grouped in 7 clinical (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and 3 immunologic (antiphospholipid antibodies, complement proteins, SLE- specific antibodies) domains, and weighted from 2 to 10. Patients accumulating ≥10 points are classified.The potential implications of having very high scores on disease severity and subsequent prognosis. This multiphase methodologic approach and classification system using a hierarchically clustered criteria established a paradigm shift in the classification of SLE.


image


Compliment 3 and Compliment 4 in SLE

While standard laboratory testing for SLE includes antinuclear antibody (ANA) and anti-double-stranded DNA (anti-dsDNA) among other autoantibodies, complement activation has proven pivotal in the pathogenesis of SLE-related immune complex damage.

Complement activation plays a key role in the pathophysiology of SLE and it is recommended to continue monitoring serum levels of C3 and C4 to assess for disease activity.

image


Our Solutions

Goldsite offers autoimmune disease panel test including C3 & C4 on our Specific Protein total solutions


Model

Level of automation
GPP-100

方形

POCT
Omlipo
画板 5
Automatic
Aristo
8ec08c6e2e4566bf146cd5fe09e09fd
Fully-automatic


Reference:
[1] HK actress Kathy Chow Hoi-mei dies at age 57. (2023, December 13). Retrieved December 15, 2023, from chinadailyhk website: https://www.chinadailyhk.com/article/366381#HK-actress-Kathy-Chow-Hoi-mei-dies-at-age-57
[2] Lim, R. Y. (2023, December 14). Death of actress Kathy Chow: Beijing police detain man who leaked her medical records. The Straits Times. Retrieved from https://www.straitstimes.com/life/entertainment/death-of-actress-kathy-chow-beijing-police-detain-man-who-leaked-her-medical-records
[3] Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey‐Goldman, R., … Lerstrøm, K. (2019). 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & Rheumatology, 71(9), 1400–1412. https://doi.org/10.1002/art.40930
[4] Sandhu, V., & Quan, M. (2017). SLE and Serum Complement: Causative, Concomitant or Coincidental? The Open Rheumatology Journal, 11(doi: 10.2174/1874312901711010113), 113–122. https://doi.org/10.2174/1874312901711010113
About Goldsite Diagnostics Inc.


GOLDSITE DIGANOSTICS INC. is a leading manufacturer of IVD products dedicated to the healthcare sector. With over 24 years of expertise in the IVD industry, Goldsite has established itself as a trusted partner since 1999. With a team of experts in the field of diagnostics technology and a passion for improving healthcare, we strive to bring cutting-edge products to market that meet the evolving needs of health providers and patients. Engaged in R&D, manufacturing, and marketing of clinical laboratory devices and reagents, Goldsite has a portfolio of products covering specific proteins, chemistry, chemiluminescence, and POCT platform, as well as associated reagents. All products live up to global standards with CE marking and have been exported to more than 80+ countries.


简介02


企业微信截图_16800822242331

Blue and White Artistic Four-Panel Storyboard

Our Vision

Our vision is to deliver state-of-art solutions that enhance patient care and improve health outcomes. We are dedicated to providing healthcare professionals with the tools they need to deliver accurate and reliable diagnoses, while also making medical diagnostics more accessible and affordable for all. We aim to make a positive impact on global health and well-being.


Follow Us

For more information, stay connected with us on our social media platforms to keep up-to-date with the latest industry news and trends, as well as insights and updates from our company. Follow us on Facebook, LinkedIn, YouTube, Twitter to be the first to know about our new products and services, events, and exciting R&D updates.


Link to our social media platform:

LinkedIn Facebook X(Twitter) YouTube TikTok






See Goldsite's latest trend on social media.

Goldsite Diagnostics Inc., founded in 1999, is a leading Chinese diagnostics manufacturer specializing in in-vitro diagnostics devices and reagents.

Quick Links

Product Links

Get in touch

    (+86)-755-26890807

        (+86)-755-26897973
   export@goldsite.com.cn

 

Copyright © 1999- 2023 Goldsite Diagnostics Inc., All rights reserved.